{"name":"Hokkaido Gastrointestinal Cancer Study Group","slug":"hokkaido-gastrointestinal-cancer-study-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Briplatin","genericName":"Briplatin","slug":"briplatin","indication":"Other","status":"phase_1"},{"name":"Krestin","genericName":"Krestin","slug":"krestin","indication":"Other","status":"phase_3"},{"name":"USEL/Leucovorin","genericName":"USEL/Leucovorin","slug":"usel-leucovorin","indication":"Rescue after high-dose methotrexate therapy","status":"phase_3"}]}],"pipeline":[{"name":"Briplatin","genericName":"Briplatin","slug":"briplatin","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Krestin","genericName":"Krestin","slug":"krestin","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"USEL/Leucovorin","genericName":"USEL/Leucovorin","slug":"usel-leucovorin","phase":"phase_3","mechanism":"Leucovorin is a folate analog that inhibits the enzyme dihydrofolate reductase, which is involved in DNA synthesis and repair.","indications":["Rescue after high-dose methotrexate therapy","Dihydropyrimidine dehydrogenase deficiency"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxNajg1SmliUTQ3TlpGeWJSRXRXejFyUnVQczE2RV9zcGJwZksySlBQNXdfN0U1VjA2Qm9aWFNIMnNjV3hZUFIteGstSGQwRnN2XzdKQlRXSFJnei1iSXRNYkE2ZUk2V25sYTVHNlBzQU0zelN1cHpYMEMxaWNMd0k3SEltdWdIWnpxdGd5bTVsOHlfczJuZTJDdHIwamszNmxHc0tCNENfLU5GUnVkQmwtTGxLaXgxcjlLRm41MzRaY1pXbHhjZ3pwZ3ZTajZHVUx3bE9xcEVUSzloS2p4X2dtR3FDajJGdDNMcGp5WXk3d0V1U0pGTVRQQ21rWVc2VlVz?oc=5","date":"2025-11-24","type":"trial","source":"PR Newswire","summary":"GlycoNex and Hokkaido University Hospital Launch Study to Advance Glycan-Directed ADC Development in Gastric Cancer - PR Newswire","headline":"GlycoNex and Hokkaido University Hospital Launch Study to Advance Glycan-Directed ADC Development in Gastric Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE8wMDl0cXB6cG5QcFA1Mm1lR2lNRDR6cFlraHpGTHBDVGpFaFlyOHNPamwyTWZrcGhsbDdwSk9rbkZ5WEVQYlZwaWUwcGtHUjdzRm5JN2lpYjlaUDQ2V1BR?oc=5","date":"2024-11-16","type":"trial","source":"nature.com","summary":"A multicenter, phase II trial of triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for highly emetogenic chemotherapy in breast cancer (PATROL-II) - nature.com","headline":"A multicenter, phase II trial of triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for highly eme","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFA2VFdOTm1QV3VhUGlmc1k0OXJtTkh1N0lKVk9VQ1RvTERHVXMxLUZ6Z2NXZDJHOGI4aXV6R2hoQzBsNXYxa0FOX1UycFZZb3RGTzdTMV93UW9ubWJ4bTNV?oc=5","date":"2024-09-16","type":"pipeline","source":"nature.com","summary":"Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors - nature.com","headline":"Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFA1SkxzRlBTUjdxMk5WZUx4V210U2wwRFM3dTRWRC1Wc1NRQmlzQzVFLVZ3ekhUMzUwMGJfbGYwUjhZMVU2NUNKR3FDMUx3OXFLNlNXXzZ4WVhvemswZUFObU04RndzSnJs?oc=5","date":"2024-05-20","type":"pipeline","source":"Wiley Online Library","summary":"DEN Open | JGES Endscopy Journal - Wiley Online Library","headline":"DEN Open | JGES Endscopy Journal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTFA1cHJfN2tVbkdTUGZyOUh3QnQ3dDNxVlI3ZWVxcTczakNZWE1heHE2ZzBQUGllZ2M2Z0loYlFCMndibFJqekM2M0ZydVN2b05PUElKWER0UjZpT1Y1cFl2MXVSWUhGWGx4SlJDMTFTcEhPcGhlZ294aHVrdw?oc=5","date":"2019-08-15","type":"regulatory","source":"acsjournals.onlinelibrary.wiley.com","summary":"A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia - acsjournals.onlinelibrary.wiley.com","headline":"A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with c","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPR0pCUVdZdXVsRVFFTk5TWHk1VUsxSk05UGdDekNuZWxFT0tDM3Y2b1hNWnlxUUxoMWZYZEtxa3VCVHhMYXV1QUNLUDAzbTJqZmNBRnBQdlRFYTFST21jNk5FYmlPVVBsWUQ1LUlkV1g4S1VmRWRpTk8xLTI2UHJUQUQ1aEVuLWVWUTc4WUxTRmljVVdlV2hweDFMODBkdw?oc=5","date":"2019-04-08","type":"pipeline","source":"healthcare-in-europe.com","summary":"Identifying a key player in gut defense development - healthcare-in-europe.com","headline":"Identifying a key player in gut defense development - healthcare-in","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1MSkYzYnM4RExpN3ZZdm5Yd2JJTXpEMmdCanRzM0hXeTg3RHNybkxMbk0zZVFKTWFrZTFySnhVWUxVd0xTWm9PdXZpRG9MQWc5TW84?oc=5","date":"2014-01-28","type":"trial","source":"nature.com","summary":"Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1) - nature.com","headline":"Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)","sentiment":"positive"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":1,"phase_3":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}